Related Experiment Video
Updated: Dec 20, 2025

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
Endpoint surrogacy in oncology Phase 3 randomised controlled trials
Jianrong Zhang1, Meagan R Pilar2, Xiaofei Wang3
1Department of General Practice, Melbourne Medical School; Cancer in Primary Care Research Group, Primary Care Collaborative Cancer Clinical Trials Group (PC4), Centre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne; Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia. jianrong.zhang@uniemelb.edu.au.
Abstract:
Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint-instead of overall survival-would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.
More Related Videos
07:40Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery
Published on: May 16, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
Treatment Resistant Cancers
Clinical Trials: Overview